No big deal that nuisance lawsuit, cj wants more stock!
OK, Maranto for the sake of others due diligence to come to your conclusion Maranto , why did the chairman of the audit committee quit with same timing of the complaints being brought to the Board of Directors ... just happenstance?
Is Mr. Klein lying in his filed complaint about the chain of events through audit committee chairman resignation and retaliation by firing the CFO?... will he do so under oath during a jury trial.
Buy some stock all of you high risk tolerant investors.
X agrees we are possibly onto something here, will the bio-tech funds take that risk. Really need them to get OMER shareholder's reward , a flying high share price for the risk they took, POSSIBLY higher now than when signing up for the IPO shares ??
The truth will likely be somewhere in between the CFO's allegation and the Company's shrug off, as always, the loser will point to semantical misunderstanding(depends on what the meaning of 'is 'is'). Be advised a USA president can do it, so could a ceo/cfo/cao/cto
Most won;t take the risk in this era of scandals, but cj, Scoop up those shares cj at black Friday prices ... and may the force be with you.
Happy Turkeyday everybody. Count your blessings, thank a few in your life that are looking out for you ... there is more to life than picking the next high flier.
Hope ???? What's the time frame for new oversight to make a difference IF there are problems ...
Daniel K. Spiegelman Elected to Board of Directors of Omeros SEATTLE, Dec 09, 2009 /PRNewswire via COMTEX News Network/ -- Omeros Corporation today announced that its Board of Directors has elected Daniel K. Spiegelman to serve on the Company's Board. Mr. Spiegelman has also been appointed to serve as Chairman of the Audit Committee. "We are very pleased to welcome Dan to our Board and look forward to working with him," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "Dan brings a substantial depth and breadth of financial experience in public biotech companies. He will be a valuable asset to Omeros as we prepare to bring our products to market." "I am excited to be joining Omeros' Board," stated Daniel Spiegelman. "The strength of the Company's management team and pipeline provide significant and multiple opportunities to advance science and improve the lives of patients. I look forward to contributing to the Company's success." Mr. Spiegelman has over 25 years of executive management, finance and operations experience. He was senior vice president and chief financial officer at CV Therapeutics prior to and during its acquisition by Gilead earlier this year. Prior to that, he was employed by Genentech, where he served as Treasurer and held a number of other senior financial positions. Mr. Spiegelman also serves on the boards of directors and chairs the audit committees of Affymax, Cyclacel Pharmaceuticals and Oncothyreon, all publicly traded biopharmaceutical companies. He earned his M.B.A. from the Stanford Graduate School of Business and his B.A. in economics from Stanford University.